Lead
   About 600 experts from nearly 300 companies in 20 countries took part in ChinaBio Partnering Forum 2010, making the event the country's biggest international cooperation forum in bio-med field. And the participants included the world's leading pharmaceutical and bio-tech companies (Pfizer, Bayer, and Johnson & Johnson) as well as law firms and consultants (Balloch, OrbiMed, Fidelity Investment, and McKinsey).
 
 
 

ChinaBio Partnering Forum 2010 Brings China Biotech to the World

     After the opening of Cold Spring Harbor Asia Conferences in April, Suzhou is under the spotlight once again in the world life science community when BioBay, ChinaBio, and EBD Group jointly held on June 23-24 ChinaBio Partnering Forum 2010 at Dushu Lake Convention Hotel. About 600 experts from nearly 300 companies in 20 countries took part in the event, making the event the country's biggest international cooperation forum in bio-med field. And the participants included the world's leading ph... [more]
 
 
Suzhou BioBay Creates Core Competitiveness by Offering Professional Services
     BioBay has built a number of public platforms providing Public Analytical Service and Antibody Technology Service among others and the number of services that have been used as of this April totals at 18,320. "We have more employees in service than in investment promotion," the general manager said. "We offer one-stop services, such as helping companies to apply for various preferential policie... [more]
 
President Schropp of EBD: We Will Come Back
     As one of the forum organizers, Carola Schropp, President of EBD Group, said that this forum was very successful and she also got much positive feedback. "Maybe not next year, but we will definitely come back," she said with a smile. "We have more than 600 meetings scheduled including one-and-one meetings. People are happy to talk with each other. In addition, people have more meetings outside... [more]
 
OrbiMed Asia Advocates Integration of Domestic and Foreign Resources
     Dr. Jonathan Wang, Senior Managing Director at OrbiMed Asia, attended the Forum. He said that the world's largest healthcare-dedicated investment firm was looking for bio-med companies backed up with strong domestic needs and capable of integrating Chinese and foreign resources. Dr. Wang defined three factors for identifying the attractive investment appeal of an enterprise, namely, the low c... [more]
 
Senior Hutchison VP Encourages Domestic Companies to Cooperate with Global Leaders
     Senior VP Wei Jianzhong of Business Development and Corporate Planning of Hutchison MediPharma, the domestic leader of new drug R&D, attended the Forum and his advice for domestic start-ups was to turn their eyes to the world leaders for cooperation. In order to convince their foreign partners, domestic companies should try to improve their lab records so as to win over potential partners with ... [more]
 
Founder of Kinesis Advises Chinese Researchers to Treasure Traditional Chinese Medicines
     When discussing the topic of how to improve new drug R&D efficiency, Dr. Kees Groen, founder and GM of Kinesis, an independent and privately owned consulting company based in the Netherlands aiming to facilitate a fast and high quality drug development process, made an insightful suggestion to the management of Chinese companies. He believed that Chinese pharmaceutical enterprises should not si... [more]
 
Dr. Xin Ma from Bayer Schering Believes One-to-One Meetings are More Effective
     Dr. Ma said the visit to Suzhou helped her to have a profound understanding of domestic market. "I visited the BioBay and talked to some local pharmaceutical companies," she said. "I'm impressed by the rapid development in the field in China. I had thought the venue of such a high-level global forum must be either Shanghai or Beijing. But it was held here in Suzhou." She believed that it was go... [more]
 
AstraZeneca Sees Industrial Collaboration as General Trend in Bio-Med Sector
     At ChinaBio Partnering Forum 2010 jointly organized by Suzhou BioBay, ChinaBio, and EBD Group at Cold Spring Harbor Asia Conference Center, Dr. Richard Wang, Director of Strategic Alliance and Collaboration at AstraZeneca, one of the world's leading biopharmaceutical companies based in UK, said cooperation was a general trend in the global bio-med community. As an experienced expert in the fi... [more]
 
CEO Stevenson of DesignMedix: One-and-One Meeting Is very Useful
     Lynnor B. Stevenson, CEO of DesignMedix, was impressed by SIP's elegant environment and fast-growing economy during her first visit to Suzhou. DesignMedix is a company dedicated to develop drugs to meet the high demand arising from drug resistance in multiple diseases. Stevenson assessed that the one-and-one meetings of the forum is a useful platform for rising bio-med enterprises to look for... [more]
 
 
 
 
Co-produced by
Hosted by
 
Welcom/Opeing Remarks:
Carola Schropp, MBA, MTS - President & Founder, EBD Group
Greg B. Scott - President & Founder, ChinaBio· LLC
Barry Yang - Chairman, Suzhou Industrial Park
Yuwen Liu, MBA - Chairwoman & CEO, BioBay
Keynote Panel: Partnering Landscape in China-Keeping Pace with Change
David Chen, MD, MBA - Executive Vice President & COO, 3SBio Inc.
Edward Hu, MBA - COO, WuXi AppTec
Kewen Jin, PhD - General Manager, Charles River Greater China
Xin Ma, PhD - Head of Global Drug Discovery-Innovation Center China, Bayer Schering Pharma
Greg Wiederrecht, PhD, CLP - VP & Head, External Scientific Affairs, Worldwide Licensing, Merck Research Laboratories
Speakers:
Brian Cunningham, JD - Senior Counsel and Co-chair of Life Science Group,Morrison & Foerster LLP
Jie Liu D'Elia, PhD, MBA - VP, International Business Development, Simcere Pharma
Alex Fowkes, JD - Executive Director, Head of R&D Business Development, Pfizer Inc.
Michael Heerde, PhD, MBA - Director, Strategy and Business Development, Bayer Healthcare China
Ruediger Herrmann, PhD - Partner, WilmerHale
Avery Ince, MD, PhD - Medical Director, MSD China
Shawn Shiqing Li, JD, PhD - Associate, Blank Rome, LLP
Esther H. Lim, JD - Founding Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai Office
Martina Molsbergen - CEO, C14 Consulting Group, LLC
John V. Oyler, MBA - former CEO, BioDuro, Inc.
Rajesh Parekh, PhD - Director, Head of Asia Healthcare Practice, McKinsey & Company
Eric Pierce - Publisher, BioCentury
J. Robert (Bob) Powell, PharmD - Scientific Advisor, Roche (China) Holding Ltd.
Jianzhong (David) Shen, JD, PhD - Asia Regional IP Counsel, Eli Lilly
Maria Song, PhD, MD - President, VPS-CRO Group
Howard Sui, PhD, MBA - Managing Director, Merck Serono China
Julian Thurston - Partner and Co-chair of Life Sciences Department, Morrison & Foerster LLP, UK
Breaux Walker - Managing Director, JMP Securities LLC
Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia
Ningling Wang, JD - Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai Office
Richard Wang, PhD, MBA - Director, Strategic Alliance and Collaboration, AstraZeneca
Xiaochuan Wang, PhD - Chairman & CEO, Sundia MediTech Co., Ltd.
Huacheng Wei, PhD - President, Beijing Pharmaceutical Group Co., Ltd.
Jimmy Wei, PhD, MBA - Senior Vice President, Business Development and Corporate Planning, Hutchison MediPhama Limited
Ian Wisenberg - Senior Vice President, Strategic Development, ChinaBio· LLC
Xiaobing Wu, PhD - General Manager, Pfizer China
Dajun Yang, MD, PhD - Co-Founder, President & CEO, Ascentage Pharma
Yanning Yi, MBA - Executive Director, The Balloch Group
Alfred W. Zaher, JD - Partner, Blank Rome LLP
Dan Zhang, MD, MPH - Chairman & CEO, Fountain Medical Development Ltd.
Ian Zhang - Head of Corporate Development, Asia Pacific, Life Technologies
Tony Zhang, PhD - Managing Director & Site Head, Lilly Global R&D, China
Larry Zhu, PhD, MBA - Director, External Scientific Affairs & Business Development, Janssen Pharmaceutical R&D, Asia Pacific

Preliminary List of Participating Companies?
0-9
3D BioOptima Co. Ltd. China
3SBio Inc. China
A
A2 Bioscience Singapore
Abbott China
Abgent United States
Access Medical Systems United States
Acorn Campus China
Ajinomoto Pharmaceuticals Co., Ltd. Japan
Alexandria Real Estate Equities, Inc. United States
Alexza Pharmaceuticals, Inc. United States
Analis s.a. Belgium
AnaptysBio, Inc. United States
Argusina (Shanghai) Ltd. China
Ascentage Pharma China
Ascepion Pharmaceuticals China
AstraZeneca United Kingdom
AstraZeneca Pharmaceutical Company China
aTyr Pharma Inc China
AusBiotech Ltd Australia
Australian Trade Commission Australia
AWEX Belgium
B
Bachem AG Switzerland
Baxter Healthcare China
Bayer Schering Pharma AG Germany
Benitec Ltd Australia
BIA Separations GmesBH Austria
BioAtla LLC United States
BioBay China
BioCentury United States
BioFocus United Kingdom
Biotech Finances France
Blank Rome LLP United States
Bone Therapeutics Belgium
braymed China
Britannia Pharmaceuticals United Kingdom
Burnet Institute Australia
C
C14 Consulting Group, LLC United States
Cardiatis Belgium
Catalysis Argentina SA Argentina
Certech Belgium
Cevec Pharmaceuticals GmbH Germany
ChemPartner Denmark
ChinaBio? LLC China
Chiome Biosciences Inc. Japan
Chiral Quest (Suzhou) Co., Ltd. China
College of Pharmacy, Yantai University China
Copenhagen Capacity Denmark
Coris BioConcept Belgium
CPR Pharma Services Pty Ltd Australia
CrystalGenomics, Inc. South Korea
CSL Biotherapies Asia Pacific Ltd Hong Kong
Cyagen Biosciences China
D
Daiichi Sankyo Group United States
DANSK BIOTEK Denmark
Davies Collison Cave Australia
Delphi Genetics Belgium
Department of Innovation, Industry, Science and Research Australia
DesignMedix Inc United States
DNAVision Belgium
Dong-A Pharmaceutical South Korea
E
Easton Associates United States
EBD Group Germany
Eddingpharm China
Efficient Pharma Management Corporate Taiwan
Eli Lilly Trading (Shanghai) Co., Ltd China
ERA Consulting Australia
Ethypharm China
EUROFINS ADME BIOANALYSES France
EyeGene, Inc. South Korea
F
FABpharma France
Fujian Medical University China
FusoGen Pharmaceuticals, Inc. China
G
Genediag. Biotech, Kusan China
Gilead Sciences, Inc. United States
H
Hamilton Desanctis and Cha LLP United States
Hanmi Pharm. South Korea
healthcare angel United States
HUYA Bioscience China
I
IDEX Health & Science LLC United States
IDT Australia Limited Australia
Innovation China UK United Kingdom
International Project & Business Management Belgium
Invida Group Pte Ltd Singapore
Invida Group Pte Ltd Singapore
Ironwood Pharmaceuticals United States
it4ip Belgium
J
Japan Tobacco Pharma United States
Jijun Zhou China
K
Kibow Biotech Inc United States
Kinesis Pharma B.V. Netherlands
L
LAXAI United States
London Genetics United Kingdom
LTS Lohmann Therapie-Systeme AG Germany
Life Technologies United States
M
MBHB United States
mdc pharmaceuticals India
Medinoah China
Merck & Co.,Inc United States
Merck Serono China
Morrison & Foerster LLP China
MW Bridges China
N
New Stock Capital Sweden
Nucleus Network Limited Australia
O
Ocean University of China China
Otsuka Pharmaceutical Co., Ltd. Japan
Oxford BioMedica plc United Kingdom
P
PAA Laboratories GmbH Austria
Pfizer China
Pharma-GPS, LLC United States
Phytopharm plc United Kingdom
Ping Ge China
R
Ranbaxy Laboratories Limited India
Roche/Ventana United States
RXB Management Consulting China
S
Saint Nicholas Hospital Egypt
sanofipasteur China
SciClone Pharmaceuticals, Inc. United States
See-D4 Pty Ltd Australia
Shanghai Joyous Paradise Enterprise Management Co., Ltd. China
Sinova Pharmaceuticals China
Stainwei Biotech, Inc China
State Goverment of Victoria, Australia Australia
Summit plc United Kingdom
SuperGen, Inc. United States
SuppreMol GmbH Germany
Synergion Biotech, Inc United States
Sypharma Pty Ltd Australia
T
Teva Pharmaceutical Industries Israel
The Balloch Group China
Thomson Reuters China
Trident Clinical Research Australia
Trius Therapeutics United States
V
Valletta Health Netherlands
W
Wave 80 Biosciences United States
WilmerHale Germany
X
Xuyue (Beijing) Sci.&Tech. Co., Ltd. China
 
Suzhou Industrial Park Administrative Committee.2004 Copyright. All rights reserved